Critical Contrast: Synageva Biopharma (GEVA) & Sunesis Pharmaceuticals (SNSS)
Synageva Biopharma (NASDAQ: GEVA) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both biotechnology & medical research – nec companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
This table compares Synageva Biopharma and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
38.2% of Sunesis Pharmaceuticals shares are owned by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Synageva Biopharma and Sunesis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sunesis Pharmaceuticals has a consensus price target of $4.16, indicating a potential upside of 12.74%.
Valuation and Earnings
This table compares Synageva Biopharma and Sunesis Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$2.54 million||49.76||-$38.02 million||($1.75)||-2.11|
Synageva Biopharma has higher earnings, but lower revenue than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than Synageva Biopharma, indicating that it is currently the more affordable of the two stocks.
Sunesis Pharmaceuticals beats Synageva Biopharma on 7 of the 8 factors compared between the two stocks.
Synageva Biopharma Company Profile
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company’s other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for Synageva Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synageva Biopharma and related companies with Analyst Ratings Network's FREE daily email newsletter.